TY - JOUR
T1 - Implications of bacteriophage- And bacteriophage component-based therapies for the clinical microbiology laboratory
AU - Caflisch, Katherine M.
AU - Patel, Robin
N1 - Funding Information:
R.P. is supported by UM1 AI104681-01, R01 AR056647, and R21 AI125870. K.M.C. is supported by T32 AR056950.
Funding Information:
We gratefully acknowledge Larry J. Prokop for his medical library expertise and assistance in curating the collection of articles which inform this review. We thank Raymond Schuch (ContraFect) for his thoughtful review of the manuscript. R.P. reports grants from ContraFect, CD Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, and Shionogi (monies are paid to Mayo Clinic), serving as a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, Selux Dx, GenMark Diagnostics, PathoQuest, and Qvella (monies are paid to Mayo Clinic), patents on a Bordetella pertussis/B. parapertussis PCR and an antibiofilm substance issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, receiving editor?s stipends from ASM and IDSA, and receiving honoraria from the NBME, Up-to-Date, and the Infectious Diseases Board Review Course. K.M.C. has no conflicts to report. R.P. is supported by UM1 AI104681-01, R01 AR056647, and R21 AI125870. K.M.C. is supported by T32 AR056950.
Publisher Copyright:
© 2019 American Society for Microbiology. All Rights Reserved.
PY - 2019
Y1 - 2019
N2 - Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.
AB - Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.
KW - Bacteriophages
UR - http://www.scopus.com/inward/record.url?scp=85069947430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069947430&partnerID=8YFLogxK
U2 - 10.1128/JCM.00229-19
DO - 10.1128/JCM.00229-19
M3 - Article
C2 - 31092596
AN - SCOPUS:85069947430
SN - 0095-1137
VL - 57
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 8
M1 - e00229-19
ER -